pharma

Ten years of retail sales in three months. Two years’ worth of digital transformation in two months. Those are the eye-opening stats from McKinsey and Microsoft, respectively, about the acceleration of business forced by the COVID-19 pandemic. It’s no surprise that a similar fast-forwarding has happened in pharma marketing. Pharma companies and agencies scrambled to
0 Comments
WALTHAM, Mass.–(BUSINESS WIRE)–Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest TGaS report entitled, “Omnichannel Marketing Center of Excellence Landscape.” Omnichannel Marketing is the orchestration of multiple marketing channels to provide a consistent message to customers at various points during their journey – an important function within
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it expects net product revenue from Jelmyto sales for the second quarter ended June 30, 2021, to be approximately $13.0 million, representing an increase of over 70% compared
0 Comments
ET INTELLIGENCE GROUP: The latest guidelines on Covid treatment released by the health ministry have made sweeping changes by excluding drugs such as ivermectin, azithromycin, doxycycline, zinc tablets, favipiravir and plasma therapy from the list of approved treatments for Covid patients and recommending extreme caution for the emergency use of remdesivir and tocilizumab. The guidelines
0 Comments
The Cyclodextrins in Pharma market research report is the high quality report having in-depth market research studies. The report offers an overview of the market, which briefly describes the market condition and the leading segments. The report proposes the estimated market size and the expected global revenue for the forecast period of Cyclodextrins in Pharma
0 Comments
The top pharma marketing articles in 2020 reflect the mix of news that epitomized the year of the pandemic. Take the most-read story, for instance. It was about a familiar theme—drug pricing—but through the COVID-19 lens, as Gilead Sciences’ first-to-market treatment remdesivir got a going-over by cost-effectiveness watchdogs. Reputation stories were popular in 2020. But again, the
0 Comments
Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore.  The main objective of our study is to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposomes.
0 Comments
The medicines developer has locked down a key approval to test its own offering against a multi-billion-dollar drug in a 12-week observational study into neuropathic pain. Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US. The cannabinoid medicines developer is set to
0 Comments
Insiders foresee recovery this year JASIM UDDIN HAROON | Published: January 09, 2021 08:31:56 | Updated: January 09, 2021 15:20:33 The pharmaceutical industry’s growth slowed significantly last year in the aftermath of Covid-19 pandemic. The life-saving drug market expanded at 6.5 per cent in the third quarter of 2020 to September, down from the annual
0 Comments
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, ‘The possibility of permanent loss is the risk I worry about… and every practical investor I know worries about.’ It’s only natural to consider a company’s balance sheet when you examine how risky it is, since debt is often
0 Comments
NEW YORK–(BUSINESS WIRE)–Jul 10, 2021– WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company’s initial public offering conducted in September 2020 (the “IPO” or “Offering”); and/or (b) between September 18, 2020 and June 17, 2021, both
0 Comments
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. Pharma companies are expected to continue their strong performance in Q1 FY22 due to
0 Comments
Philip Morris International (PMI), the multinational cigarette and tobacco manufacturing giant, is set to buy British pharmaceutical company Vectura for £1 billion ($1.5billion). Vectura is involved in developing a pioneering inhaler that is supposed to work against the Covid-19 virus. The Marlboro manufacturer is offering 150p per share for the London-listed company. This deal is
0 Comments
The physician marketing sector was driven predominantly by in-person communications, until the Covid-19 pandemic, which spurred a reported 90% of physicians treating patients remotely. This presented a challenge for pharmaceutical marketers to efficiently connect with physicians across telehealth platforms. The shift in marketing dynamics to engage physicians has accelerated the adoption of digital mediums to
0 Comments
NEW YORK, July 9, 2021 /PRNewswire/ — WHY: , Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company’s initial public offering conducted in September 2020 (the “IPO” or “Offering”); and/or (b) between September 18, 2020 and June
0 Comments